Stratec Se

Stratec Se Net Debt

The Net Debt of Stratec Se (SBS.DE) as of Oct 13, 2026 is 98.84 M EUR. In the previous year, Net Debt was 81.81 M EUR — a change of 20.81% (higher).

Net Debt

98.84 MEUR

YoY

20.81%

Last updated:

Net Debt of Stratec Se is 2025 98.84 M EUR. Net Debt of Stratec Se was 2024 81.81 M EUR. It decreases by 20.81% higher compared to the previous year.

The Stratec Se Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
44.91 M EUR
Jan 1, 2019
69.23 M EUR
Jan 1, 2020
70.43 M EUR
Jan 1, 2021
36.57 M EUR
Jan 1, 2022
63.08 M EUR
Jan 1, 2023
107.85 M EUR
Jan 1, 2024
81.81 M EUR
Jan 1, 2025
98.84 M EUR
The Stratec Se Net Debt history
YEARNet DebtYoY
98.84 MEUR+20.81%
81.81 MEUR-24.15%
107.85 MEUR+70.98%
63.08 MEUR+72.47%
36.57 MEUR-48.07%
70.43 MEUR+1.73%
69.23 MEUR+54.17%
44.91 MEUR+73.59%
25.87 MEUR-34.84%
39.70 MEUR-173.40%
-54.09 MEUR+40.87%
-38.40 MEUR—
Access this data via the Eulerpool API

Stratec Se Stock analysis

What does Stratec Se do? The company Stratec SE is a German company operating in the medical technology industry. It was founded in 1984 and has since become a leading provider of automation solutions and diagnostic instruments. Stratec's business model is based on the development and production of devices and systems used in medical diagnostics. The company focuses in particular on the areas of immunology, clinical chemistry, and hematology. Stratec also offers innovative solutions in microscopy and cell analysis. In the "automation solutions" division, Stratec develops systems for the automation of laboratory processes. These are mainly used in clinical diagnostics to accelerate and simplify workflow. Examples include sample identification systems, pipetting robots, and analysis devices. In the "in vitro diagnostics" division, Stratec offers products for determining blood values. This includes devices for determining glucose, cholesterol, and hemoglobin levels, as well as devices for infection diagnostics and tumor and allergy diagnostics. Another division of Stratec is "microscopy." The company manufactures automated microscope systems, primarily used in biomedical research to analyze cells and tissues. In the "cell analysis" division, Stratec offers innovative methods for analyzing cells, such as cell growth and vitality determination. Stratec always focuses on tailoring the design of its products to the needs of its customers. High flexibility in device development and manufacturing is therefore an important factor in the company's success. In addition to device development and production, Stratec also provides services related to its products. These include installation, maintenance, and on-site repair of devices for customers. Stratec SE operates internationally and has branches in Europe, Asia, and America. The company employs over 1,000 people worldwide. Overall, Stratec SE is a successful and renowned provider of medical devices and systems for automating laboratory processes. With its diverse product portfolio and high flexibility in customer support, Stratec has earned a leading position in the industry. Stratec Se is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stratec Se stock

Net Debt of Stratec Se is 98.84 M EUR in 2025.

Net Debt of Stratec Se changed from 81.81 M EUR to 98.84 M EUR, representing a 20.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Stratec Se since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Stratec Se historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Stratec Se

All Key Metrics — Stratec Se